Search Results - "Madeleine, Noëlly"
-
1
AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer
Published in iScience (20-11-2020)“…The receptor tyrosine kinase AXL is associated with epithelial plasticity in several solid tumors including breast cancer and AXL-targeting agents are…”
Get full text
Journal Article -
2
C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer
Published in Nature communications (10-01-2022)“…Epidemiological studies have established a positive association between obesity and the incidence of postmenopausal breast cancer. Moreover, it is known that…”
Get full text
Journal Article -
3
The Arabidopsis (ASHH2) CW domain binds monomethylated K4 of the histone H3 tail through conformational selection
Published in The FEBS journal (01-10-2020)“…Chromatin post‐translational modifications are thought to be important for epigenetic effects on gene expression. Methylation of histone N‐terminal tail lysine…”
Get full text
Journal Article -
4
Identification of Inhibitors for the Lutheran Blood Group Glycoprotein - Laminin 511/521 Interaction by Molecular Modelling and Simulation Techniques
Published in Current computer-aided drug design (01-01-2018)“…Drepanocytosis is a genetic blood disorder characterized by red blood cells that assume an abnormal, rigid, sickle shape. In the pathogenesis of vaso-occlusive…”
Get more information
Journal Article -
5
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Published in Journal for immunotherapy of cancer (01-11-2023)“…BackgroundIn NSCLC, mutations in LKB1/STK11, KEAP1, SMARCA4, and KRAS are associated with unfavorable treatment outcomes, regardless of treatment modality.1–4…”
Get full text
Journal Article -
6
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
Published in Journal for immunotherapy of cancer (01-11-2020)“…BackgroundAXL is implicated in resistance to immunotherapy. Bemcentinib (BGB324), a first-in-class, oral, selective and potent AXL kinase inhibitor, enhances…”
Get full text
Journal Article -
7
The Arabidopsis (ASHH2) CW domain binds monomethylated K4 of the histone H3 tail through conformational selection
Published in The FEBS journal (2020)“…Chromatin post‐translational modifications are thought to be important for epigenetic effects on gene expression. Methylation of histone N‐terminal tail lysine…”
Get full text
Journal Article -
8
Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract STK11 (LKB1) is a tumor suppressor, and loss-of-function mutations contribute to tumorigenesis. Mutations in the STK11 gene (STK11m) are present in ~…”
Get full text
Journal Article -
9
AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial
Published in Blood (02-11-2023)“…Acute myeloid leukemia can be treated by intensive chemotherapy. However, this treatment is unsuitable for a subset of patients because of age and/or…”
Get full text
Journal Article